Zhongsheng Ruichuang Biotechnology

Guangdong Zhongsheng Ruichuang Biotechnology, also known as RayNovation, is a clinical-stage Chinese biotechnology company specializing in the development of innovative small molecule drugs. The company primarily focuses on infectious diseases, respiratory conditions, and metabolic disorders such as non-alcoholic steatohepatitis (NASH). As a subsidiary of Guangdong Zhongsheng Pharmaceutical, RayNovation has successfully commercialized Leritrelvir (RAY1216), a 3CL protease inhibitor for the treatment of COVID-19 in China. Its pipeline includes Onradivir (ZSP1273), a first-in-class PB2 inhibitor for Influenza A currently in Phase 3 clinical trials. Additionally, the company is advancing ZSP1601, a novel pan-phosphodiesterase inhibitor for NASH, and ZSP0678 for idiopathic pulmonary fibrosis. RayNovation aims to address significant unmet medical needs through its robust R&D platform and strategic focus on high-incidence diseases.